Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial.

• Published in: Health Technology Assessment
• Main Authors: Howard, Dena R, Munir, Talha, McParland, Lucy, Rawstron, Andy C, Chalmers, Anna, Gregory, Walter M, O'Dwyer, John L, Smith, Alison, Longo, Roberta, Varghese, Abraham, Smith, Alexandra, Hillmen, Peter
• Format: Text
• Language: English
• Published: NIHR Journals Library 2017
• Subjects: Research Article; Arctic
• Online Access: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5494513/; http://www.ncbi.nlm.nih.gov/pubmed/28628003; https://doi.org/10.3310/hta21280